Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 18/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 15/20 | 0.48 |
| ▸ | CTSD | P07339 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11938695 | 0.91 | BACE1 (0.46) | BACE1BACE2CTSD | |
| SCHEMBL11025468 | 0.89 | BACE1 (0.56) | BACE1BACE2CTSD | |
| SCHEMBL15835728 | 0.88 | BACE1 (0.48) | BACE1BACE2CTSDKCNH2 | |
| Hydrochloric Acid SCHEMBL11025691 | 0.88 | BACE1 (0.55) | BACE1BACE2CTSD | |
| SCHEMBL11886512 | 0.85 | BACE1 (0.45) | BACE1BACE2CTSDKCNH2 | |
| SCHEMBL15817729 | 0.85 | BACE1 (0.46) | BACE1BACE2CTSDKCNH2 | |
| SCHEMBL11888108 | 0.85 | BACE1 (0.45) | BACE1BACE2CTSDKCNH2 | |
| SCHEMBL18598025 | 0.85 | BACE1 (0.45) | BACE1BACE2CTSDKCNH2 | |
| SCHEMBL15150094 | 0.85 | BACE1 (0.45) | BACE1BACE2CTSDKCNH2 | |
| SCHEMBL11027450 | 0.84 | BACE1 (0.37) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2665732-B1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2016-03-30 | — | — | EP | disclosed |
| US-8940734-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940734-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940734-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-27 | — | — | US | disclosed |
| US-20140142091-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20140142091-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20140142091-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
| US-8592408-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-11-26 | — | — | US | disclosed |
| US-20130203740-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-20130203740-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-8338407-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-12-25 | — | — | US | disclosed |
| US-8338407-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-12-25 | — | — | US | disclosed |
| US-8338407-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | BACE1 1/4885BACE2 3/4885CTSD 469/4885 |
| US-20140142091-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | BACE1 1/4885BACE2 3/4885CTSD 469/4885 |
| US-20130203740-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | BACE1 1/4885BACE2 3/4885CTSD 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.